title: Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease.
authors.forename: Naim
authors.initials: N
authors.lastname: Alkhouri
authors.forename: Vera
authors.initials: V
authors.lastname: Hupertz
authors.forename: Lori
authors.initials: L
authors.lastname: Mahajan
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003125:Colostomy / Q000009:adverse effects*; D003424:Crohn Disease / Q000150:complications*; D005260:Female; D006801:Humans; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab